ABSTRACT

METHOD OF DETECTING RESISTANCE TO CANCER THERAPY

We describe a polymorphic variant of a *BIM* (*BCL2L11*) gene which comprises, in 5' to 3' order, the nucleotide sequence set out in SEQ ID NO: 5 followed immediately by the nucleotide sequence set out in SEQ ID NO: 7. The *BIM* polymorphic variant may be characterised by lacking the nucleotide sequence set out in SEQ ID NO: 6. It may be used to detect BCR-ABL-independent TKI-resistance (resistance to treatment with tyrosine kinase inhibitors) for chronic myelogenous leukaemia, c-KIT/PDGFR-independent TKI-resistance for gastrointestinal stromal tumours (GIST), EGFR-independent TKI-resistance for non-small cell lung cancer (NSCLC) or JAK2-independent TKI-resistance for a myeloproliferative disorder, in an individual comprising such a polymorphism.

Figure 1